TR200101884T2 - Farnesil transferaz inhibitörleri olarak 4-merkaptopirolidin türevleri. - Google Patents

Farnesil transferaz inhibitörleri olarak 4-merkaptopirolidin türevleri.

Info

Publication number
TR200101884T2
TR200101884T2 TR2001/01884T TR200101884T TR200101884T2 TR 200101884 T2 TR200101884 T2 TR 200101884T2 TR 2001/01884 T TR2001/01884 T TR 2001/01884T TR 200101884 T TR200101884 T TR 200101884T TR 200101884 T2 TR200101884 T2 TR 200101884T2
Authority
TR
Turkey
Prior art keywords
values
mercaptopyrolidine
derivatives
transferase inhibitors
farnesyl transferase
Prior art date
Application number
TR2001/01884T
Other languages
English (en)
Inventor
Thomas Boyle Francis
Huw Davies David
Wedderburn Kenny Peter
Stanley Matusiak Zbigniew
Beverley Scholes Peter
Michael Wardleworth James
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Limited filed Critical Zeneca Limited
Publication of TR200101884T2 publication Critical patent/TR200101884T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmasötik açidan kabul edilebilir bir seyreltici veya tasiyici ile birlikte, formül I'e sahip bir ras farnesilasyon inhibitörü burada R1, örnegin H dir ve diger degerler tarifname içinde tanimlandigi gibidir;R2, örnegin H ve diger digerler tarifname içinde tanimlandigi gibidir; R3, örnegin H veya tarifnamede tarifedilen degerlere sahip bir sübstitüenttir; P,0-3 dür ve burada R3 degerleri ayni veya farkli olabilir; L, örnegin-CO-NH2- gibi bir baglayici gruptur ve diger degerleri tarifnamede tarifedildigi gibidir;A,fenil, naftil bagimsiz olarak O, N ve S'den heteroatoma sahip bir 5-10 üyeli monosiklik veya bisiklik heteroaril halkasindan seçilir; veya R2=H oldugu zaman bunun bir-S-S-dimerini; veya bir enantiomerini, diastereomerini, farmasötik açidan kabul edilebilir bir tuzunu, ön-ilacini veya solvatini ihtiva eden farmasötik terkipler. Belirli bir kullanim alani kanser tedavisidir. (Sekil I).
TR2001/01884T 1995-08-04 1996-07-30 Farnesil transferaz inhibitörleri olarak 4-merkaptopirolidin türevleri. TR200101884T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9515975.2A GB9515975D0 (en) 1995-08-04 1995-08-04 Chemical compounds

Publications (1)

Publication Number Publication Date
TR200101884T2 true TR200101884T2 (tr) 2002-06-21

Family

ID=10778742

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/01884T TR200101884T2 (tr) 1995-08-04 1996-07-30 Farnesil transferaz inhibitörleri olarak 4-merkaptopirolidin türevleri.
TR1998/00147T TR199800147T1 (tr) 1995-08-04 1996-07-30 Farnesil transferaz inhibitörleri olarak 4-merkaptopirolidin türevleri.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR1998/00147T TR199800147T1 (tr) 1995-08-04 1996-07-30 Farnesil transferaz inhibitörleri olarak 4-merkaptopirolidin türevleri.

Country Status (23)

Country Link
US (2) US6232338B1 (tr)
EP (1) EP0842151A1 (tr)
JP (1) JPH11510178A (tr)
KR (1) KR100502770B1 (tr)
CN (2) CN1101380C (tr)
AU (1) AU720353B2 (tr)
BR (1) BR9609701A (tr)
CA (1) CA2226671C (tr)
CZ (1) CZ293694B6 (tr)
GB (1) GB9515975D0 (tr)
HU (1) HUP9802857A3 (tr)
IL (1) IL123155A0 (tr)
MX (1) MX9800946A (tr)
MY (1) MY141457A (tr)
NO (2) NO316624B1 (tr)
NZ (1) NZ313696A (tr)
PL (1) PL190873B1 (tr)
RU (1) RU2191773C2 (tr)
SK (1) SK14598A3 (tr)
TR (2) TR200101884T2 (tr)
TW (1) TW345575B (tr)
WO (1) WO1997006138A1 (tr)
ZA (1) ZA966610B (tr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204293B1 (en) 1995-11-06 2001-03-20 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6693123B2 (en) 1995-11-06 2004-02-17 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6310095B1 (en) 1995-11-06 2001-10-30 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6221865B1 (en) 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
AU4020897A (en) * 1996-08-17 1998-03-06 Zeneca Limited 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
ES2387211T3 (es) 1997-05-07 2012-09-18 University Of Pittsburgh Inhibidores de proteínas isoprenil transferass
PT1025088E (pt) 1997-10-22 2002-01-30 Astrazeneca Ab Derivados de imidazole e sua utilizacao como inibidores de farnesil proteino transferase
WO1999020612A1 (en) 1997-10-22 1999-04-29 Astrazeneca Uk Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
EP1054865A1 (en) * 1998-02-10 2000-11-29 AstraZeneca UK Limited Farnesyl transferase inhibitors
GB9930318D0 (en) * 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
GB9930317D0 (en) * 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CA2521826C (en) 2003-04-11 2013-08-06 Jennifer L. Reed Recombinant il-9 antibodies and uses thereof
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
CA2538884C (en) 2003-09-16 2010-09-21 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US20050288298A1 (en) * 2004-03-18 2005-12-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital TREATMENT OF SYNUCLEINOPATHIES
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
WO2007092285A2 (en) * 2006-02-02 2007-08-16 Link Medicine Corporation Treatment of synucleinopathies
PT2292663E (pt) 2006-08-28 2013-11-04 Kyowa Hakko Kirin Co Ltd Anticorpos monoclonais humanos antagonistas específicos de light humano
JP5456658B2 (ja) 2007-03-30 2014-04-02 メディミューン，エルエルシー 抗体製剤
CN101376656A (zh) * 2007-08-30 2009-03-04 山东轩竹医药科技有限公司 培南衍生物
ES2533874T3 (es) 2007-10-31 2015-04-15 Medimmune, Llc Armazón proteico
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
MX2011005096A (es) * 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2012133881A1 (en) * 2011-03-30 2012-10-04 Canon Kabushiki Kaisha Polymerizable monomer, polymeric compound, charge control agent containing the polymeric compound, and developer bearing member and toner which contain the charge control agent
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
JP2015533832A (ja) 2012-10-09 2015-11-26 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗Ｃ１６ｏｒｆ５４抗体およびその使用方法
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
KR102362630B1 (ko) 2013-08-26 2022-02-15 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102614642B1 (ko) 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
DK3229838T3 (da) 2014-12-11 2020-10-19 Pf Medicament Anti-C10orf54-antistoffer og anvendelser deraf
HRP20230046T1 (hr) 2015-03-03 2023-03-03 Kymab Limited Protutijela, upotreba i postupci
WO2017011323A1 (en) 2015-07-10 2017-01-19 University Of Maryland, Baltimore Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US20200131266A1 (en) 2017-05-31 2020-04-30 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
CA3065301A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
JP7256796B2 (ja) 2017-10-13 2023-04-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
WO2020016459A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
JPS60233076A (ja) 1984-05-03 1985-11-19 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
CA1281720C (en) 1984-11-08 1991-03-19 Makoto Sunagawa Carbapenem compounds and production thereof
KR880006244A (ko) 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법
GB8921635D0 (en) 1989-09-25 1989-11-08 Fujisawa Pharmaceutical Co 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
CA2036163C (en) 1990-02-14 2001-06-19 Makoto Sunagawa Novel beta-lactam compounds and their production
NO178498C (no) 1990-02-23 1996-04-10 Sankyo Co Analogifremgangsmåte ved fremstilling av terapeutisk aktive karbapenemderivater
GB9107363D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5185248A (en) 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation
JPH0578360A (ja) 1991-01-31 1993-03-30 Banyu Pharmaceut Co Ltd ２−［２−（スルフアモイルアルキル）ピロリジニルチオカルバペネム誘導体
GB9107342D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
GB9107341D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
AU651887B2 (en) 1991-06-04 1994-08-04 Sankyo Company Limited 1-methylcarbapenem derivatives, their preparation and their use as antibiotics
JPH04368386A (ja) 1991-06-18 1992-12-21 Sankyo Co Ltd １−メチルカルバペネム−３−カルボン酸の製造法
US5360798A (en) 1991-07-04 1994-11-01 Shionogi Seiyaku Kabushiki Kaisha Aminooxypyrrolidinylthiocarbapenem compounds
DE69204007T2 (de) 1991-10-11 1996-03-21 Squibb & Sons Inc Verwendung von Farnesyl-Protein Transferaseinhibitoren zur Herstellung eines Arzneimittels zur Blockierung von durch Ras-Oncogenen hervorgerufenen neoplastischen Transformationen von Zellen.
JPH05239058A (ja) 1991-12-17 1993-09-17 Fujisawa Pharmaceut Co Ltd ３−ピロリジニルチオ−１−アザビシクロ［３．２．０ヘプト−２−エン−２−カルボン酸化合物
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
FI103046B (fi) 1992-03-11 1999-04-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrrolidinyylitiokarbapeneemij ohdannaisten valmistamiseksi
CA2091309A1 (en) 1992-03-26 1993-09-27 Frederic H. Jung Antibiotic compounds
GB9304156D0 (en) * 1992-03-26 1993-04-21 Zeneca Ltd Antibiotic compounds
EP0636133A1 (en) 1992-04-13 1995-02-01 Fujisawa Pharmaceutical Co., Ltd. Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents
CA2099818A1 (en) 1992-07-21 1994-01-22 Frederic H. Jung Antibiotic compounds
EP0581501B1 (en) 1992-07-21 1998-09-09 Zeneca Limited Antibiotic carbapenem compounds
EP0581502B1 (en) 1992-07-21 1998-10-21 Zeneca Limited Antibiotic carbapenem compounds
EP0590885B1 (en) 1992-09-28 2000-03-15 Zeneca Limited Antibiotic carbapenem compounds
CA2106330A1 (en) 1992-10-07 1994-04-08 Patrice J. Siret Antibiotic compounds
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
JPH09500109A (ja) 1993-06-18 1997-01-07 メルク エンド カンパニー インコーポレーテッド ファルネシル蛋白質トランスフェラーゼの阻害剤
WO1995009001A1 (en) 1993-09-30 1995-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5840918A (en) 1994-03-15 1998-11-24 Eisai Co., Ltd. Isoprenyl transferase inhibitors
CA2155448A1 (en) * 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
US5571835A (en) * 1994-09-29 1996-11-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU707537B2 (en) 1995-07-31 1999-07-15 Anthera Pharmaceuticals, Inc. Pyrrolidine derivatives having phospholipase a2 inhibitory activity
JP3115285B2 (ja) 1999-04-27 2000-12-04 徳光 中ノ瀬 合成樹脂体を利用した水上施設

Also Published As

Publication number Publication date
NO20024950L (no) 1998-04-03
CA2226671C (en) 2005-04-05
MY141457A (en) 2010-04-30
BR9609701A (pt) 1999-03-23
ZA966610B (en) 1997-02-04
CN1101380C (zh) 2003-02-12
JPH11510178A (ja) 1999-09-07
HUP9802857A3 (en) 1999-05-28
CZ293694B6 (cs) 2004-07-14
EP0842151A1 (en) 1998-05-20
NO980467D0 (no) 1998-02-03
KR100502770B1 (ko) 2007-03-15
HUP9802857A2 (hu) 1999-04-28
US6541491B1 (en) 2003-04-01
GB9515975D0 (en) 1995-10-04
IL123155A0 (en) 1998-09-24
AU6622396A (en) 1997-03-05
KR19990036110A (ko) 1999-05-25
PL190873B1 (pl) 2006-02-28
PL324819A1 (en) 1998-06-22
CN1197453A (zh) 1998-10-28
NO980467L (no) 1998-04-03
AU720353B2 (en) 2000-06-01
US6232338B1 (en) 2001-05-15
MX9800946A (es) 1998-04-30
WO1997006138A1 (en) 1997-02-20
CZ30998A3 (cs) 1998-06-17
CA2226671A1 (en) 1997-02-20
RU2191773C2 (ru) 2002-10-27
NO20024950D0 (no) 2002-10-15
TR199800147T1 (tr) 1998-04-21
NO316624B1 (no) 2004-03-15
SK14598A3 (en) 1998-09-09
TW345575B (en) 1998-11-21
CN1377647A (zh) 2002-11-06
NZ313696A (en) 2000-01-28

Similar Documents

Publication Publication Date Title
TR200101884T2 (tr) Farnesil transferaz inhibitörleri olarak 4-merkaptopirolidin türevleri.
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
TW218018B (tr)
MY114792A (en) Farnesyl transferase inhibitors,their preparation and pharmaceutical compositions comprising them
ES2194986T3 (es) Compuestos de carbonil-piperazinilo y piperidinilo que inhiben la farnesil-protein-transferasa.
GEP20032896B (en) 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
TR199800720T2 (tr) Farnesil transferaz inhibe eden 2-kinolon türevleri.
TR199801935T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
KR950703554A (ko) 피페라진 유도체 및 그의 염(piperazine derivatives and salts thereof)
NO324229B1 (no) 2-hydroksymutilinkarbamat-derivater, anvendelse derav, farmasoytisk sammensetning samt fremgangsmate for fremstilling av en slik forbindelse
NO960632D0 (no) Nye bis-naftalimider for behandling av kreft
DE69330601T2 (de) Serotoninergische ergolin derivate
KR930006024A (ko) 이미다조 인돌리진 유도체 및 그의 제조방법
ATE213241T1 (de) Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
EP0315434A3 (en) Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same
DE59108566D1 (de) Heteroarylmethylbenzole-Aromatasehemmer
BR0016115A (pt) Derivados peptìdicos de acriloìla, processo para sua preparação e seu uso como agentes inibidores de tumor
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
SE9203824D0 (sv) Benzofuranylimidazole derivatives a process for the preparation and therapeutical compositions containing the same
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
ATE21908T1 (de) Derivate von 1,4-diaminocyclitol, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
RU94038051A (ru) Гетероциклические производные, способ их получения, фармацевтическая композиция и способ лечения
TH13812EX (th) อนุพันธ์ของคาร์บาพีเนมต่อต้านจุลินทรีย์, การ เตรียมสารเหล่านั้นและการใช้สารเหล่านั้นในการ รักษา